Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma

被引：43

作者：

Allmeroth, Kira ^{[1
]}

Horn, Moritz ^{[2
]}

Kroef, Virginia ^{[1
]}

Miethe, Stephan ^{[1
]}

Mueller, Roman-Ulrich ^{[3
,4
,5
,6
]}

Denzel, Martin S. ^{[1
,3
,6
]}

机构：

[1] Max Planck Inst Biol Ageing, Joseph Stelzmann Str 9b, D-50931 Cologne, Germany

[2] Acus Labs GmbH, Max Planck Inst Biol Ageing, Joseph Stelzmann Str 9b, D-50931 Cologne, Germany

[3] Univ Cologne, CECAD Cluster Excellence, Joseph Stelzmann Str 26, D-50931 Cologne, Germany

[4] Univ Cologne, Fac Med, Dept Internal Med 2, Kerpener Str 62, D-50937 Cologne, Germany

[5] Univ Cologne, Univ Hosp Cologne, Kerpener Str 62, D-50937 Cologne, Germany

[6] Univ Cologne, Ctr Mol Med Cologne CMMC, Robert Koch Str 21, D-50931 Cologne, Germany

来源：

LEUKEMIA | 2021年 / 35卷 / 03期

关键词：

20S PROTEASOME;

D O I：

10.1038/s41375-020-0989-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：887 / 892

页数：6

共 15 条

[1] Spectrum and functional validation of PSMB5 mutations in multiple myeloma [J].

Barrio, Santiago ;

Stuehmer, Thorsten ;

Da-Via, Matteo ;

Barrio-Garcia, Clara ;

Lehners, Nicola ;

Besse, Andrej ;

Cuenca, Isabel ;

Garitano-Trojaola, Andoni ;

Fink, Severin ;

Leich, Ellen ;

Chatterjee, Manik ;

Driessen, Christoph ;

Martinez-Lopez, Joaquin ;

Rosenwald, Andreas ;

Beckmann, Roland ;

Bargou, Ralf C. ;

Braggio, Esteban ;

Stewart, A. Keith ;

Raab, Marc S. ;

Einsele, Hermann ;

Kortuem, K. Martin .

LEUKEMIA, 2019, 33 (02) :447-456

[2] In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells [J].

Chauhan, Dharminder ;

Tian, Ze ;

Zhou, Bin ;

Kuhn, Deborah ;

Orlowski, Robert ;

Raje, Noopur ;

Richardson, Paul ;

Anderson, Kenneth C. .

CLINICAL CANCER RESEARCH, 2011, 17 (16) :5311-5321

[3] Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib [J].

Harshbarger, Wayne ;

Miller, Chase ;

Diedrich, Chandler ;

Sacchettini, James .

STRUCTURE, 2015, 23 (02) :418-424

[4] Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets [J].

Hideshima, Teru ;

Mitsiades, Constantine ;

Tonon, Giovanni ;

Richardson, Paul G. ;

Anderson, Kenneth C. .

NATURE REVIEWS CANCER, 2007, 7 (08) :585-598

[5]

Horn Moritz, 2018, Oncotarget, V9, P9838, DOI 10.18632/oncotarget.24305

[6] Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna [J].

Kuhn, Deborah J. ;

Chen, Qing ;

Voorhees, Peter M. ;

Strader, John S. ;

Shenk, Kevin D. ;

Sun, Congcong M. ;

Derno, Susan D. ;

Bennett, Mark K. ;

Van Leeuwen, Fijs W. B. ;

Chanan-Khan, Asher A. ;

Orlowski, Robert Z. .

BLOOD, 2007, 110 (09) :3281-3290

[7] Clinical course of patients with relapsed multiple myeloma [J].

Kumar, SK ;

Therneau, TM ;

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Rajkumar, SV ;

Fonseca, R ;

Witzig, TE ;

Lust, JA ;

Larson, DR ;

Kyle, RA ;

Greipp, PR .

MAYO CLINIC PROCEEDINGS, 2004, 79 (07) :867-874

[8] The resistance mechanisms of proteasome inhibitor bortezomib [J].

Lü S. ;

Wang J. .

Biomarker Research, 1 (1)

[9] Mechanisms of proteasome inhibitor action and resistance in cancer [J].

McConkey, David J. ;

Zhu, Keyi .

DRUG RESISTANCE UPDATES, 2008, 11 (4-5) :164-179

[10] Molecular basis of resistance to proteasome inhibitors in hematological malignancies [J].

Niewerth, Denise ;

Jansen, Gerrit ;

Assaraf, Yehuda G. ;

Zweegman, Sonja ;

Kaspers, Gertjan J. L. ;

Cloos, Jacqueline .

DRUG RESISTANCE UPDATES, 2015, 18 :18-35

← 1 2 →